| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8229600 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 8 Pages |
Abstract
The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection, and a trend for long-term risk of second cancers. EBRT should be avoided in patients with low- and intermediate-risk EC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Carien L. M.D., Ph.D., Remi A. M.D., Marnix L.M. M.D., Carla C. M.D., Jan J. M.D., Ph.D., Jan-Willem M. M.D., Ludy C.H.W. M.D., Ph.D., Elisabeth M.D., Ph.D., Lonneke V. Ph.D., Wim L.J. M.Sc., PORTEC Study Group PORTEC Study Group,